First and only drug releasing system to provide extended local delivery of a cancer medication into the bladder, with 82 percent of patients achieving complete response without the need for ...
Credit: J&J. The New Drug Application is supported by data from cohort 2 of the single-arm, phase 2b SunRISe-1 study. The device remains in the bladder and provides a sustained release of gemcitabine ...
FDA designates FF-10832 as an orphan drug for biliary tract cancer, promising enhanced treatment options for this aggressive malignancy. The FDA has granted orphan drug designation to FF-10832 ...
Sequential intravesical gemcitabine and docetaxel is associated with better oncologic outcomes compared with additional BCG in patients with BCG-unresponsive NMIBC and warrants a trial. Sequential ...
1 Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China 2 Department of Pathology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China ...
This study, known as ESPAC4, reported on with long-term follow-up of 732 patients in a phase 3, open-label, multicentre, randomised clinical trial of GemCap vs gemcitabine. Patients were seen in 92 ...
Urothelial carcinoma has long been treated with chemotherapy as the frontline standard of care, but recent trial results in the space have potential to add to the treatment armamentarium and improve ...
The approval, which is based on results from the phase 3 KEYNOTE-966 trial, marks the sixth indication for pembrolizumab in gastrointestinal cancer. The FDA has approved pembrolizumab (Keytruda; Merck ...
Patients who received gemcitabine followed by docetaxel experienced a delay in the need for radical cystectomy. Sequential intravesical gemcitabine/docetaxel treatment for high-risk nonmuscle-invasive ...
CARY, N.C.--(BUSINESS WIRE)--Focal Medical, Inc., a privately held, biopharmaceutical company developing novel precision therapeutic products today announced successful completion of the nonclinical ...
No new agent has improved overall survival in patients with unresectable or metastatic urothelial carcinoma when added to first-line cisplatin-based chemotherapy. In this phase 3, multinational, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback